{"id":55518,"date":"2026-01-26T21:03:40","date_gmt":"2026-01-26T13:03:40","guid":{"rendered":"https:\/\/flcube.com\/?p=55518"},"modified":"2026-01-26T21:03:41","modified_gmt":"2026-01-26T13:03:41","slug":"astrazenecas-soliris-wins-nmpa-approval-for-pediatric-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55518","title":{"rendered":"AstraZeneca\u2019s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis"},"content":{"rendered":"\n<p><strong>AstraZeneca plc<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ:\u202fAZN<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>Soliris (eculizumab)<\/strong>, a <strong>C5 complement inhibitor<\/strong>, for the treatment of <strong>refractory generalized myasthenia gravis (gMG)<\/strong> in <strong>pediatric patients aged 6 years and older<\/strong> who are <strong>anti\u2011acetylcholine receptor (AChR) antibody positive<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>AstraZeneca plc (NASDAQ:\u202fAZN)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Soliris (eculizumab)<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Refractory generalized myasthenia gravis (gMG) in pediatric patients (\u22656 years)<\/td><\/tr><tr><td><strong>Biomarker<\/strong><\/td><td>Anti\u2011AChR antibody positive<\/td><\/tr><tr><td>**Mechanism<\/td><td>C5 complement inhibitor (first\u2011in\u2011class)<\/td><\/tr><tr><td>**Administration<\/td><td>Intravenous every 2 weeks (following induction)<\/td><\/tr><tr><td>**Previous NMPA Approvals<\/td><td>PNH, aHUS, adult gMG, NMOSD<\/td><\/tr><tr><td>**Approval Date<\/td><td>20\u202fJan\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Selective inhibition of terminal complement C5<\/strong> activation, preventing the formation of membrane attack complex (MAC) that destroys healthy cells in autoimmune disorders<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>World\u2019s first C5 inhibitor<\/strong> to enter the market; addresses uncontrolled complement activation that causes the immune system to attack the body\u2019s own cells<\/li>\n\n\n\n<li><strong>Clinical Utility:<\/strong> Provides <strong>rapid and sustained symptom control<\/strong> in refractory gMG patients who fail standard immunosuppressive therapies<\/li>\n\n\n\n<li><strong>Administration:<\/strong> IV infusion every 2 weeks following an initial 4\u2011week induction period, ensuring consistent complement blockade<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Myasthenia Gravis Prevalence<\/strong><\/td><td>200,000<\/td><td>700,000<\/td><\/tr><tr><td><strong>Refractory gMG (AChR+)<\/strong><\/td><td>45,000<\/td><td>160,000<\/td><\/tr><tr><td><strong>Pediatric Refractory gMG (\u22656 years)<\/strong><\/td><td>8,500<\/td><td>30,000<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Corticosteroids, immunosuppressants, IVIG, thymectomy<\/td><td><\/td><\/tr><tr><td><strong>C5 Inhibitor Penetration<\/strong><\/td><td>12\u202f%<\/td><td>25\u202f%<\/td><\/tr><tr><td><strong>Annual Treatment Cost (USD)<\/strong><\/td><td>$180,000<\/td><td>$400,000<\/td><\/tr><tr><td><strong>Market Value (2030E)<\/strong><\/td><td>\u00a54.5\u202fbillion<\/td><td>$6.4\u202fbillion<\/td><\/tr><tr><td><strong>Soliris Peak Share<\/strong><\/td><td>18\u202f%<\/td><td>15\u202f%<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>\u00a5810\u202fmillion<\/td><td>$960\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ultomiris<\/strong> (ravulizumab, AstraZeneca) \u2013 Next\u2011generation C5 inhibitor with longer dosing interval (8 weeks), approved for adult gMG<\/li>\n\n\n\n<li><strong>Vyvgart<\/strong> (efgartigimod, argenx) \u2013 FcRn antagonist, approved for adult gMG in China<\/li>\n\n\n\n<li><strong>Soliris<\/strong> \u2013 <strong>First and only C5 inhibitor<\/strong> approved for <strong>pediatric gMG<\/strong> in China; established safety profile across multiple indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Label Expansion:<\/strong> Pediatric gMG approval extends Soliris\u2019s <strong>dominance in complement\u2011mediated diseases<\/strong>, leveraging existing <strong>hospital infusion center infrastructure<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> AstraZeneca\u2019s <strong>Alexion manufacturing network<\/strong> (Dublin, Ireland) supplies China; <strong>local fill\u2011finish partnership<\/strong> with <strong>WuXi Biologics<\/strong> ensures supply security<\/li>\n\n\n\n<li><strong>Reimbursement Pathway:<\/strong> Eligible for <strong>NRDL Category\u202f1b<\/strong> (innovative drugs for rare diseases); expected <strong>50\u201160\u202f% price discount<\/strong> offset by <strong>volume increase<\/strong> in pediatric segment<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Positions Ultomiris for <strong>pediatric gMG label extension<\/strong> following Soliris\u2019s regulatory pathway; <strong>switch program<\/strong> to migrate stable patients to 8\u2011week dosing<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding market penetration, reimbursement negotiations, and revenue forecasts for Soliris in pediatric gMG. Actual results may differ due to competitive dynamics, pricing pressures, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced that China\u2019s National Medical Products Administration (NMPA) has approved Soliris&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[130,770,871,15,24],"class_list":["post-55518","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-astrazeneca","tag-az","tag-nasdaq-azn","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca\u2019s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced that China\u2019s National Medical Products Administration (NMPA) has approved Soliris (eculizumab), a C5 complement inhibitor, for the treatment of refractory generalized myasthenia gravis (gMG) in pediatric patients aged 6 years and older who are anti\u2011acetylcholine receptor (AChR) antibody positive.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55518\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca\u2019s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced that China\u2019s National Medical Products Administration (NMPA) has approved Soliris (eculizumab), a C5 complement inhibitor, for the treatment of refractory generalized myasthenia gravis (gMG) in pediatric patients aged 6 years and older who are anti\u2011acetylcholine receptor (AChR) antibody positive.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55518\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T13:03:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-26T13:03:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55518#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55518\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca\u2019s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis\",\"datePublished\":\"2026-01-26T13:03:40+00:00\",\"dateModified\":\"2026-01-26T13:03:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55518\"},\"wordCount\":415,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"AZ\",\"NASDAQ: AZN\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55518#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55518\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55518\",\"name\":\"AstraZeneca\u2019s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-26T13:03:40+00:00\",\"dateModified\":\"2026-01-26T13:03:41+00:00\",\"description\":\"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced that China\u2019s National Medical Products Administration (NMPA) has approved Soliris (eculizumab), a C5 complement inhibitor, for the treatment of refractory generalized myasthenia gravis (gMG) in pediatric patients aged 6 years and older who are anti\u2011acetylcholine receptor (AChR) antibody positive.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55518#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55518\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55518#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca\u2019s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca\u2019s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced that China\u2019s National Medical Products Administration (NMPA) has approved Soliris (eculizumab), a C5 complement inhibitor, for the treatment of refractory generalized myasthenia gravis (gMG) in pediatric patients aged 6 years and older who are anti\u2011acetylcholine receptor (AChR) antibody positive.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55518","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca\u2019s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis","og_description":"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced that China\u2019s National Medical Products Administration (NMPA) has approved Soliris (eculizumab), a C5 complement inhibitor, for the treatment of refractory generalized myasthenia gravis (gMG) in pediatric patients aged 6 years and older who are anti\u2011acetylcholine receptor (AChR) antibody positive.","og_url":"https:\/\/flcube.com\/?p=55518","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-26T13:03:40+00:00","article_modified_time":"2026-01-26T13:03:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55518#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55518"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca\u2019s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis","datePublished":"2026-01-26T13:03:40+00:00","dateModified":"2026-01-26T13:03:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55518"},"wordCount":415,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","AZ","NASDAQ: AZN","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55518#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55518","url":"https:\/\/flcube.com\/?p=55518","name":"AstraZeneca\u2019s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-26T13:03:40+00:00","dateModified":"2026-01-26T13:03:41+00:00","description":"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced that China\u2019s National Medical Products Administration (NMPA) has approved Soliris (eculizumab), a C5 complement inhibitor, for the treatment of refractory generalized myasthenia gravis (gMG) in pediatric patients aged 6 years and older who are anti\u2011acetylcholine receptor (AChR) antibody positive.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55518#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55518"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55518#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca\u2019s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55518"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55518\/revisions"}],"predecessor-version":[{"id":55519,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55518\/revisions\/55519"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}